- Home
- NIE vs YMAB Comparison
NIE vs YMAB Comparison
Compare NIE & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- YMAB
- Stock Information
- Founded
- NIE 2007
- YMAB 2015
- Country
- NIE United States
- YMAB United States
- Employees
- NIE N/A
- YMAB N/A
- Industry
- NIE Investment Managers
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- YMAB Health Care
- Exchange
- NIE Nasdaq
- YMAB Nasdaq
- Market Cap
- NIE 612.1M
- YMAB 631.1M
- IPO Year
- NIE N/A
- YMAB 2018
- Fundamental
- Price
- NIE $23.70
- YMAB $11.14
- Analyst Decision
- NIE
- YMAB Strong Buy
- Analyst Count
- NIE 0
- YMAB 8
- Target Price
- NIE N/A
- YMAB $21.38
- AVG Volume (30 Days)
- NIE 70.5K
- YMAB 268.9K
- Earning Date
- NIE 01-01-0001
- YMAB 11-08-2024
- Dividend Yield
- NIE 9.04%
- YMAB N/A
- EPS Growth
- NIE N/A
- YMAB N/A
- EPS
- NIE N/A
- YMAB N/A
- Revenue
- NIE N/A
- YMAB $84,553,000.00
- Revenue This Year
- NIE N/A
- YMAB $10.24
- Revenue Next Year
- NIE N/A
- YMAB $20.21
- P/E Ratio
- NIE N/A
- YMAB N/A
- Revenue Growth
- NIE N/A
- YMAB N/A
- 52 Week Low
- NIE $18.61
- YMAB $5.17
- 52 Week High
- NIE $22.47
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- NIE 58.00
- YMAB 25.01
- Support Level
- NIE $22.89
- YMAB $12.47
- Resistance Level
- NIE $24.21
- YMAB $15.69
- Average True Range (ATR)
- NIE 0.27
- YMAB 0.97
- MACD
- NIE 0.05
- YMAB -0.46
- Stochastic Oscillator
- NIE 61.36
- YMAB 9.88
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.